Expression and prognostic significance of CD19 in patients with acute myelogenous leukemia with AML1-ETO positive
10.3969/j.issn.1000-484X.2016.12.019
- VernacularTitle:AML1-ETO阳性急性髓系白血病CD19的表达及其预后的意义
- Author:
Cheng BIAN
;
Ping HE
;
Chang WANG
;
Xiaoliang LIU
;
Shanshan LIU
;
Hai LIN
;
Yehui TAN
;
Sujun GAO
- Keywords:
Acute myelogenous leukemia;
AML1-ETO positive;
CD19;
Prognosis
- From:
Chinese Journal of Immunology
2016;32(12):1809-1814
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the expression and prognostic significance of CD19 in patients with Acute myelogenous leukemia with AML1-ETO positive. Methods: Clinical data of 66 patients AML with AML1-ETO positive who were newly diagnosed from Jan 2010 to Dec 2015 were collected. To retrospectively analyze the relationship between clinical characteristics and expression of CD19,so dose the prognosis. Results:The positive rate of CD19 expressing in AML with AML1-ETO positive was 50. 0%. There were no statistically significant differences in terms of age,gender,hemoglobin,platelet,percentage of bone marrow blasts,accompanied with chromosome ,gene mutations between patients with and without CD19 expression(P>0. 05). The white blood cell count(WBC) of the CD19 negative group was higher than CD19 positive group,while showed significant difference(P=0. 027). Although the relapse-free survival (RFS) of patients with CD19 expression was higher than those without,no significant difference was calculated (P=0. 105). Patients with CD19 expression had superior overall survival ( OS ) compared to those without CD19 expression ( P = 0. 030 ) . Multivariable analysis for OS identified CD19 positivity as an independent predictor associated with better prognosis. Conclusion: The expression of CD19 in AML with AML1-ETO positive may be an indicator associated with better prognosis.
